Showing 921-930 of 23043 results for "".
Smarter Money: Let Your Practice Dollars Work Better for You
https://modernaesthetics.com/topics/practice-development/smarter-money-let-your-practice-dollars-work-better-for-you/35129/You can improve the bottom line by making sure you optimize your ROI in key areasContact Lenses As a Growth Engine
https://reachmd.com/programs/modern-optometry/contact-lenses-as-a-growth-engine/39039/How I used strategic partnerships, patient-centered service, and conversation to increase my contact lens sales by 20% in 1 year.Value of of Earlier Lipid-Lowering therapy Intensification with Evolocumab in High-Risk Populations without known significant ASCVD and with Diabetes: VESALIUS-CV Insights
https://reachmd.com/clinical-practice/cardiology/value-of-of-earlier-lipid-lowering-therapy-intensification-with-evolocumab-in-high-risk-populations-without-known-significant-ascvd-and-with-diabetes-vesalius-cv-insights/56624/At ACC 2026, Dr. Giugliano discusses an analysis of VESALIUS-CV showing evolocumab reduced MACE even without atherosclerosis.Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
https://reachmd.com/clinical-practice/cardiology/evolocumab-in-patients-without-significant-atherosclerosis-and-with-diabetes-a-cardiology-perspective-on-vesalius-cv/56744/New VESALIUS-CV data show broad cardiovascular benefits of evolocumab in high-risk primary prevention patients with diabetes and no atherosclerosis.Optimizing the Care and Quality of Life for Patients with ADPKD – Part 4: Emerging Therapies
https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-4-emerging-therapies/12680/How can you use emerging therapeutic options to treat patients with autosomal dominant polycystic kidney disease?Optimizing the Care and Quality of Life for Patients with ADPKD – Part 3: Management
https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-3-management/12679/Once a patient is diagnosed with autosomal dominant polycystic kidney disease, how can we manage them?Optimizing the Care and Quality of Life for Patients with ADPKD – Part 2: Progression and Prognostication
https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12678/Hear top strategies for monitoring disease progression and deciding courses of treatment for those with autosomal dominant polycystic kidney disease.The Clinical Significance of Imaging in the Management of ADPKD
https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12675/When managing patients with autosomal dominant polycystic kidney disease, what role does radiological imaging play?Optimizing the Care and Quality of Life for Patients with ADPKD – Part 1: Detection and Diagnosis
https://reachmd.com/programs/cme/clinical-significance-imaging-management-adpkd/12677/What are effective strategies for detecting and diagnosing patients who are at risk of autosomal dominant polycystic kidney disease?MIRASOL Insights in PROC: A Biomarker-Driven Approach
https://reachmd.com/programs/project-oncology/mirasol-proc-biomarker-approach/37252/In platinum-resistant ovarian cancer (PROC), survival is usually measured in months,1-3 and most patients will have already received multiple prior lines of therapy.4 Biomarker-driven therapy has helped change the treatment landscape.5-10 Tune in to learn more about mirvetuximab soravtansine-gynx as